Email Alert | RSS

北京大学学报（医学版） ›› 2025, Vol. 57 ›› Issue (5): 864-867. doi: 10.19723/j.issn.1671-167X.2025.05.009

• 获奖工作综述 • 上一篇    下一篇

胃癌精准诊疗技术的创建与推广

李浙民1, 季加孚2,*(), 李国新3, 李子禹1, 步召德1, 高翔宇2, 董迪4, 唐磊5, 邢晓芳6, 贾淑芹7, 郭婷8, 张连海1, 陕飞1, 季鑫1, 王安强1   

  1. 1. 北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心, 北京 100142
    2. 北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心, 消化系肿瘤整合防治全国重点实验室, 北京 100142
    3. 清华大学附属北京清华长庚医院胃肠外科, 北京 102218
    4. 中国科学院分子影像重点实验室, 中国科学院自动化研究所, 北京 100190
    5. 北京大学肿瘤医院暨北京市肿瘤防治研究所医学影像科, 北京 100142
    6. 北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤转化研究实验室, 消化系肿瘤整合防治全国重点实验室, 北京 100142
    7. 北京大学肿瘤医院暨北京市肿瘤防治研究所分子诊断中心, 消化系肿瘤整合防治全国重点实验室, 北京 100142
    8. 北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤转化研究实验室, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142
  • 收稿日期:2025-08-01 出版日期:2025-10-18 发布日期:2025-08-28
  • 通讯作者: 季加孚
  • 基金资助:
    国家自然科学基金(92259302); 国家自然科学基金(31870805); 国家自然科学基金(U20A20371); 北京市医院管理中心人才计划(DFL20181103); 北京市医院管理中心人才计划(SML20151001); 北京市科技计划课题(D171100006517000); 北京市科技计划课题(D171100006517004)

Development and dissemination of precision medicine approaches in gastric cancer management

Zhemin LI1, Jiafu JI2,*(), Guoxin LI3, Ziyu LI1, Zhaode BU1, Xiangyu GAO2, Di DONG4, Lei TANG5, Xiaofang XING6, Shuqin JIA7, Ting GUO8, Lianhai ZHANG1, Fei SHAN1, Xin JI1, Anqiang WANG1   

  1. 1. Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China
    2. Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing 100142, China
    3. Department of Gastrointestinal Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
    4. CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China
    5. Department of Medical Imaging, Peking University Cancer Hospital & Institute, Beijing 100142, China
    6. Gastrointestinal Cancer Translational Research Laboratory, Peking University Cancer Hospital & Institute, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing 100142, China
    7. Molecular Diagnostic Center, Peking University Cancer Hospital & Institute, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing 100142, China
    8. Gastrointestinal Cancer Translational Research Laboratory, Peking University Cancer Hospital & Institute, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing 100142, China
  • Received:2025-08-01 Online:2025-10-18 Published:2025-08-28
  • Contact: Jiafu JI
  • Supported by:
    the National Natural Science Foundation(92259302); the National Natural Science Foundation(31870805); the National Natural Science Foundation(U20A20371); the Beijing Hospitals Authority Talent Plan(DFL20181103); the Beijing Hospitals Authority Talent Plan(SML20151001); the Beijing Municipal Science and Technology Plan Projects(D171100006517000); the Beijing Municipal Science and Technology Plan Projects(D171100006517004)

RICH HTML

   

PDF (PC)

摘要： 胃癌是严重威胁我国居民健康的高发恶性肿瘤, 发病率和死亡率均居前三位, 且多数患者确诊时已属进展期, 治疗难, 预后差。为攻克我国胃癌诊疗中的关键问题, 由北京大学肿瘤医院季加孚教授领衔的科研团队聚焦"胃癌精准诊疗技术的创建与推广"项目, 通过系列多中心、高水平临床研究, 建立了围术期综合治疗、个体化药物筛选、智能无创诊断、新型免疫治疗等多个方面的国际新标准, 显著提高了疗效, 降低了创伤, 从诊断、治疗、机制等多个方面实现胃癌精准诊疗技术领域的关键技术突破, 系统性地改善了胃癌的治疗效果。研究成果在国际上产生了广泛影响, 主办了中国首次国际胃癌大会, 通过全国范围内推广, 促进了胃癌精准诊疗的学科建设, 主持制定了国家卫生健康委员会胃癌诊疗指南, 该项目荣获2024年中华医学科技奖医学科学技术奖一等奖。

关键词: 胃癌, 新辅助化疗, 腹腔镜手术, 人工智能, 免疫疗法

Abstract: Gastric cancer is a high-incidence malignancy that poses a serious threat to public health in China, ranking among the top three cancers in both incidence and mortality. The majority of patients are diagnosed at an advanced stage, resulting in limited treatment options and poor prognosis. To address key challenges in gastric cancer diagnosis and treatment, a research team led by Professor Jiafu Ji at Peking University Cancer Hospital has focused on the project "Development and Dissemination of Precision Medicine Approaches in Gastric Cancer Management". Through a series of high-quality multicenter clinical studies, the team established a set of new international standards in perioperative treatment, individua-lized drug selection, intelligent noninvasive diagnostics, and novel immunotherapy strategies. These advances have significantly improved treatment efficacy and reduced surgical trauma, achieving key technological breakthroughs in diagnosis, therapy, and mechanistic understanding, and systematically enhancing outcomes for gastric cancer patients. The project ' s findings had a broad international impact, including hosting China ' s first International Gastric Cancer Congress. Through nationwide dissemination, they have promoted the development of precision diagnosis and treatment of gastric cancer as a discipline, and led the formulation of the National Health Commission's guidelines for gastric cancer diagnosis and treatment. In recognition of its achievements, the project was awarded the First Prize of the 2024 Chinese Medical Science and Technology Award.

Key words: Gastric cancer, Neoadjuvant chemotherapy, Laparoscopic surgery, Artificial intelligence, Immunotherapy

中图分类号: 

  • R735.2
1
Yang L, Zheng R, Wang N, et al. Incidence and mortality of stomach cancer in China, 2014[J]. Chin J Cancer Res, 2018, 30(3): 291- 298.
2
Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project[J]. Gastric Cancer, 2017, 20(2): 217- 225.

doi: 10.1007/s10120-016-0601-9
3
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315- 321.
4
Bang YJ, van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687- 697.
5
Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): An open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8): 1081- 1092.

doi: 10.1016/S1470-2045(21)00297-7
6
Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021(6th edition)[J]. Gastric Cancer, 2023, 26(1): 1- 25.

doi: 10.1007/s10120-022-01331-8
7
Kim IH, Kang SJ, Choi W, et al. Korean practice guidelines for gastric cancer 2024:An evidence-based, multidisciplinary approach (update of 2022 guideline)[J]. J Gastric Cancer, 2025, 25(1): 5- 114.

doi: 10.5230/jgc.2025.25.e11
8
Yin S, Xi R, Wu A, et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy[J]. Sci Transl Med, 2020, 12(549): eaaz1723.
9
Li Z, Gao X, Peng X, et al. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy[J]. Sci Adv, 2020, 6(9): eaay4211.
10
Yu J, Huang C, Sun Y, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: The CLASS-01 randomized clinical trial[J]. JAMA, 2019, 321(20): 1983- 1992.
11
Li Z, Shan F, Ying X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A randomized clinical trial[J]. JAMA Surg, 2019, 154(12): 1093- 1101.

doi: 10.1001/jamasurg.2019.3473
12
Li Z, Li Z, Jia S, et al. Depth of tumor invasion and tumor-occupied portions of stomach are predictive factors of intra-abdominal metastasis[J]. Chin J Cancer Res, 2017, 29(2): 109- 117.

doi: 10.21147/j.issn.1000-9604.2017.02.03
13
Dong D, Tang L, Li ZY, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer[J]. Ann Oncol, 2019, 30(3): 431- 438.

doi: 10.1093/annonc/mdz001
14
Dong D, Fang MJ, Tang L, et al. Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: An international multicenter study[J]. Ann Oncol, 2020, 31(7): 912- 920.

doi: 10.1016/j.annonc.2020.04.003
15
Xing X, Jia S, Leng Y, et al. An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer[J]. Oncoimmunology, 2020, 9(1): 1792038.
16
Guo T, Tang XH, Gao XY, et al. A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer[J]. Mol Cancer, 2022, 21(1): 216.

doi: 10.1186/s12943-022-01684-9
17
Ma X, Jia S, Wang G, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance[J]. Signal Transduct Target Ther, 2023, 8(1): 246.

doi: 10.1038/s41392-023-01450-3
18
Yu H, Wang M, Zhang T, et al. Dual roles of β-arrestin 1 in mediating cell metabolism and proliferation in gastric cancer[J]. Proc Natl Acad Sci USA, 2022, 119(40): e2123231119.

doi: 10.1073/pnas.2123231119
19
Guo T, Bai YH, Cheng XJ, et al. Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4[J]. Cancer Commun (Lond), 2021, 41(3): 258- 272.
20
Guan X, Cai M, Du Y, et al. CVCDAP: An integrated platform for molecular and clinical analysis of cancer virtual cohorts[J]. Nucleic Acids Res, 2020, 48(W1): W463- W471.
[1] 季加孚, 韦静涛, 季科, 步召德. 胃癌诊疗的瓶颈与破局：迈向精准化与智能化融合的新纪元[J]. 北京大学学报（医学版）, 2026, 58(2): 231-238.
[2] 步召德, 冯梦宇, 季科. 早期胃癌行前哨淋巴结导航手术的实践与思考[J]. 北京大学学报（医学版）, 2026, 58(2): 239-243.
[3] 高加勒, 张忠涛. 局部进展期直肠癌精准治疗现状与展望[J]. 北京大学学报（医学版）, 2026, 58(2): 247-250.
[4] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报（医学版）, 2026, 58(2): 257-265.
[5] 杜文, 章文博, 于尧, 刘硕, 苏惠裕, 胡耒豪, 唐祖南, 吴彬彰, 陈震, 李家琦, 王昊, 彭歆. 口腔颌面部肿瘤"数智化外科"诊疗流程探索与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 278-284.
[6] 郭芷均, 俎明, 马超, 张贺军, 张静, 丁士刚. 同时性多发早期胃癌漏诊病灶的临床病理特征[J]. 北京大学学报（医学版）, 2026, 58(2): 410-415.
[7] 潘子晨, 陈凯, 侯钰坤, 杨博涵, 张继新, 马永蔌, 田孝东, 杨尹默. 胰腺腺鳞癌临床病理特征与分子机制研究进展[J]. 北京大学学报（医学版）, 2026, 58(2): 431-435.
[8] 邓旭亮, 徐明明, 杜宸临. 人工智能驱动口腔医学：临床、科研、教学与管理的创新探索[J]. 北京大学学报（医学版）, 2025, 57(5): 821-826.
[9] 张铃福, 王港, 侯纯升, 崔龙, 王立新, 凌晓锋, 徐智. 腹腔镜下改良经胆囊管胆管引流术在胆石症治疗及胆道疾病诊断中的应用[J]. 北京大学学报（医学版）, 2025, 57(4): 748-752.
[10] 黄万伟, 沙显燊, 张艺宝, 伍国豪, 骆峰, 陈智慧, 叶东明, 李学松, 赖彩永. 完全3D腹腔镜回肠代双侧输尿管联合膀胱扩大术修复放射治疗后双侧输尿管狭窄并膀胱挛缩[J]. 北京大学学报（医学版）, 2025, 57(4): 789-795.
[11] 刘苗雨, 王思源, 裴林, 王殊. 同步应用戈舍瑞林对年轻乳腺癌患者新辅助化疗疗效的影响[J]. 北京大学学报（医学版）, 2025, 57(2): 291-297.
[12] 许克新,丁泽华. 人工智能在功能泌尿外科的应用[J]. 北京大学学报（医学版）, 2023, 55(5): 771-774.
[13] 毛海,张帆,张展奕,颜野,郝一昌,黄毅,马潞林,褚红玲,张树栋. 基于MRI前列腺腺体相关参数构建腹腔镜前列腺癌术后尿失禁的预测模型[J]. 北京大学学报（医学版）, 2023, 55(5): 818-824.
[14] 刘想,谢辉辉,许玉峰,张晓东,陶晓峰,柳林,王霄英. 人工智能对提高放射科住院医生诊断胸部肋骨骨折一致性的价值[J]. 北京大学学报（医学版）, 2023, 55(4): 670-675.
[15] 刘菊梅,梁丽,张继新,戎龙,张梓怡,吴悠,赵旭东,李挺. 411例早期胃癌及癌前病变内镜黏膜下剥离术标本的病理学评估[J]. 北京大学学报（医学版）, 2023, 55(2): 299-307.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部